Knowledge Center

SuperCom Awarded Five-Year Contact with the National Government of Latvia

SuperCom (SPCB) announced on June 4 that the company was awarded a new 5-year contract with the Latvian national government. Latvia’s Ministry of Justice will deploy SuperCom’s PureSecurity Electronic Monitoring (EM) Suite. SuperCom’s technology provides electronic monitoring of offenders using both RF House Arrest and GPS Tracking solutions.   Sonal detected the event and issued […]

Read more...

May 2020 Scorecard

The May 2020 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

Cubic Corporation Awarded Contract with British Army

Cubic Corporation (CUB) announced on June 1 that Cubic Defence U.K. was awarded a $35 million contract. Under the terms of the three-year contract, Cubic will provide support and repair of the British Army’s Area Weapons Effects Simulator (AWES) System at training facilities in the U.K. and Canada. Cubic Defence U.K. is part of the […]

Read more...

Argenx Reports Positive Phase 3 Clinical Trial Results

On May 26, argenx (ARGX) reported positive Phase 3 clinical trial results from the ADAPT trial of efgartigimod. The ADAPT trial evaluates improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score for acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients. Respondents in the trial saw an improvement of at least two points […]

Read more...

Triumph Awarded 6-Year Extension on Chinook Fleet Contract

On May 26, Triumph Group, Inc. (TGI) announced that Triumph Systems and Support received a six-year extension on its contract for an international CH-47 Chinook fleet. As part of the contract, Triumph provides maintenance, repair, and overhaul services for the fleet’s EMC-32T hydromechanical fuel control. Triumph plans to deliver the services out of its West […]

Read more...

Ultragenyx Reports Positive Initial Data on DTX401 Clinical Trial

On May 15, Ultragenyx Pharmaceutical Inc. (RARE) presented positive initial data from all three cohorts in its DTX401 clinical trial. DTX401 is an adeno-associated virus-based gene therapy. It is undergoing clinical trials for the treatment of glycogen storage disease type 1a (GSD1a). All patients demonstrated significant cornstarch reductions over time and increases in time to […]

Read more...

Kratos Awarded Sole-Source Contract from U.S. Space Force

On May 4, Kratos Defense & Security Solutions, Inc. (KTOS) announced that it was awarded a sole-source contract with the U.S. Space Force. Under the terms of the contract, Kratos will provide satellite bandwidth utilization services and continuous monitoring of commercial satellites leased by the U.S. Space Force. The contract is valued at just over […]

Read more...

April 2020 Scorecard

The April 2020 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

Akebia Announces Positive Phase 3 Clinical Trial Results

Akebia Therapeutics, Inc. (AKBA) announced positive top-line results on May 5 for the first of its two Phase 3 cardiovascular outcomes programs. The two INNO2VATE studies evaluated the efficacy and safety of Akebia’s drug vadadustat. The drug treats anemia due to chronic kidney disease in adult patients on kidney dialysis. The studies indicate that the treatment […]

Read more...

FDA Grants Accelerated Approval to Immunomedics for Trodelvy in Breast Cancer Patients

On April 22, Immunomedics, Inc. (IMMU) announced that they received accelerated FDA approval of Trodelvy™ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC). The treatment is specifically for patents who have received at least two prior therapies for metastatic disease. This is a particularly aggressive form of cancer for […]

Read more...